- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT04717336
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African Americans Study (GENE-FORECAST): Sodium Intervention Trial (SIT)
Genomics, Environmental Factors and Social Determinants of Cardiovascular Disease in African-Americans Study(GENE-FORECAST): Sodium Intervention Trial (SIT)/GENE-FORECAST SIT
Background:
Hypertension is a risk factor for heart disease. Low-sodium diets rich in fruits, vegetables, and other healthy foods are a good way to reduce blood pressure in people with hypertension. Researchers want to learn more about why African Americans seem to have the greatest benefit from certain dietary interventions.
Objective:
To better understand the body s response to adding more salt to the diet.
Eligibility:
U.S.-born African American adults ages 21 to 65 who are in good general health and took part in the GENE-FORECAST.
Design:
Participants will be screened with a medical history and physical exam. If needed, they will take a pregnancy test. These tests will be repeated during the study.
Each day for 2 weeks, participants will take 3 capsules that contain either placebo or salt. Then they will take no pills for 3 weeks. Then they will take placebo or salt capsules for 2 more weeks.
Participants will talk about the foods and drinks they have consumed over the past 24 hours. They will take a survey about their physical activity and sleep.
Participants will complete taste tasks to obtain their responses to sweetness or saltiness. Sucrose and salt detection thresholds and preferences will be assessed.
Participants will give blood and urine samples. Saliva samples will be collected from their mouth by passive drool or by spitting into a sterile tube. Skin samples will be collected from behind their ears and the inner part of their elbow, using sterile swabs. Participants will get kits to collect stool samples at home.
Participants will have 4 study visits over 7 weeks.
Study Overview
Status
Conditions
Intervention / Treatment
Detailed Description
Study Type
Enrollment (Actual)
Phase
- Early Phase 1
Contacts and Locations
Study Contact
- Name: Amadou Gaye, M.D.
- Phone Number: (301) 451-1847
- Email: amadou.gaye@nih.gov
Study Locations
-
-
Maryland
-
Bethesda, Maryland, United States, 20892
- National Institutes of Health Clinical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Description
- INCLUSION CRITERIA:
African American men and women who are former GENE-FORECAST participants between 21 and 65 years of age. This criterion is inclusive of self-identified AA of both Hispanic, Latino and non-Hispanic, Latino ethnicities. Normotensive participants with systolic blood pressure (SBP) <140 mm Hg and diastolic blood pressure (DBP) <90 mm Hg and the absence of a history of prior diagnosis of hypertension.
-Willingness and ability to participate in study procedures.
EXCLUSION CRITERIA:
- Individuals who are pregnant or breast-feeding.
- Individuals with high blood pressure or a history of hypertension.
- Individuals with a history of myocardial infarction, stroke, heart failure, diabetes, chronic liver or kidney diseases.
- Individuals who are taking antihypertensive, antidepressants, antidiabetic and antibiotic medications.
- Individuals currently participating in another NIH protocol.
- Individuals unable to provide informed consent.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Basic Science
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Triple
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Placebo Comparator: PERIOD 1
Participant will be instructed to take 3 pills per day for a total of 3 grams.
Participant will take Sodium Chloride or placebo for a two week period.
|
It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals.
Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
placebo capsules, salt treatment
|
Placebo Comparator: PERIOD 2
Participant will be instructed to take 3 pills per day for a total of 3 grams.
Participant will take Sodium Chloride or placebo for a two week period.
|
It is well established that increased dietary sodium can predispose to an increase in blood pressure; particularly in salt-sensitive individuals.
Seeking to test the hypothesis that changes in dietary sodium intake are sufficient to influence the composition of the gut microbiome in association with sodium-induced changes in vascular function, epigenome, transcriptome and blood pressure in African Americans.
placebo capsules, salt treatment
|
No Intervention: WASHOUT OUT PERIOD
Participant will have a wash-out period for three-weeks.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
What effect does increase dietary sodium intake have on vascular function and microbiome?
Time Frame: Two-Three years
|
A sub-set of salt-sensitive individuals exhibit changes in vascular function and modest elevations in blood pressure in response to relatively modest changes in dietary sodium intake.
Studies have suggested an apparent increased prevalence of salt-sensitive blood pressure among African Americans The various patterns of gut microbiome composition have been implicated in the regulation of the immune system as well as the pathogenesis of obesity, autoimmune disorders and cardiovascular disease.
|
Two-Three years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Amadou Gaye, M.D., National Human Genome Research Institute (NHGRI)
Publications and helpful links
Helpful Links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 10000070
- 000070-HG
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
IPD Plan Description
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Cardiovascular Disease
-
University of FloridaUniversity of Alabama at Birmingham; Brown UniversityCompletedCardiovascular Disease | Psychosocial Influence on Cardiovascular DiseaseUnited States
-
National Heart, Lung, and Blood Institute (NHLBI)CompletedCardiovascular Disease | Inflammatory DiseaseUnited States
-
Morehouse School of MedicineNot yet recruiting
-
Yonsei UniversityRecruitingCardiovascular DiseaseKorea, Republic of
-
Nanjing Medical UniversityNot yet recruitingCardiovascular Disease
-
M.D. Anderson Cancer CenterNational Cancer Institute (NCI)Active, not recruiting
-
AmgenCompletedCardiovascular DiseaseUnited States, Australia
-
VA Office of Research and DevelopmentEnrolling by invitationCardiovascular DiseaseUnited States
-
Penn State UniversityCalifornia Walnut CommissionCompletedCardiovascular DiseaseUnited States
Clinical Trials on SODIUM CHLORIDE
-
Imperial College LondonRoyal Brompton & Harefield NHS Foundation TrustCompletedNeuromuscular DiseasesUnited Kingdom
-
University of JenaCompletedCystic Fibrosis | RhinosinusitisGermany
-
Institut d'Anesthesiologie des Alpes MaritimesUniversité de Nice Sophia Antipolis; Medical University of GrenobleCompleted
-
Federal University of São PauloCompleted
-
Radboud University Medical CenterUnknownType1diabetes | Hypoglycemia UnawarenessNetherlands
-
Austin HealthCompletedSystemic Inflammatory Response Syndrome | Renal Impairment | OliguriaAustralia
-
Medical University of GrazCompleted
-
Osaka General Medical CenterCompletedEmergent Coronary ProcedureJapan
-
Lars Wiuff AndersenUniversity of AarhusRecruiting